Visiongain Research Reports

Title	Published	Price
Lipitor Market analysis and forecasts Report, 2007-2012, 2017 & 2023 By: Visiongain In 2006, Pfizer’s Lipitor (atorvastatin) generated global revenues of $13.6bn, making it the best selling drug in pharmaceutical history. The blockbuster medicine has single-handedly driven the overall revenue margins of the cardiovascular segment, as this \| more...	4/30/2008	$2,502.00
Mobile Remittance - A Window for the Financial Empowerment of Global Communities through Mobility By: Visiongain While the use of high-tech electronic substitutes for cash was always expected to infiltrate developed markets such as Japan, mobile wallets and electronic transfers were perceived as requiring much time to reach poorer countries. Case \| more...	4/16/2008	$2,502.00
Chinese Pharmaceutical Outlook 2008-2023 By: Visiongain This brand new report examines the prospects for the growth of pharmaceutical revenues in China. Visiongain predicts that total pharmaceutical revenues in China will increase from approximately $12bn in 2007 to over $30bn in 2013. \| more...	4/16/2008	$2,502.00
Pharmaceutical Control of Blood Diseases Market Analysis & Forecasts Report 2008 (prev. Blood Disorders Market Analysis & Forecasts Report to 2013) By: Visiongain In 2007, blood diseases cost the US's economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. \| more...	4/14/2008	$2,502.00
Blood Disorders Market Analysis & Forecasts Report to 2013 By: Visiongain In 2007, blood diseases cost the US’s economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. \| more...	4/14/2008	$2,210.00
Top-10 Biotech Companies - Market Outlook, 2008-2023 By: Visiongain The biotechnology industry is a major growth area in the global healthcare market, one upon which many companies are placing their hopes. Due to developments in monoclonal antibodies, genomics and proteomics - amongst others - \| more...	4/12/2008	$2,502.00
Mobile search 2008-2013: Profiting From Information and Advertising on the Move By: Visiongain Search has transported from the internet to the mobile and has been identified as an area of enormous growth. Mobile subscribers are currently tentative. But with growing confidence they are exploring the internet over their \| more...	3/28/2008	$2,502.00
Sleep Disorders Market Analysis 2008-2018 By: Visiongain More than 80 sleep disorders have been identified. They affect over 200 million people worldwide. The report focuses on the market for following sleep disorders: \| more...	3/25/2008	$2,502.00
The Antibacterial Drug Market Analysis 2008-2013 By: Visiongain This brand new market analysis by visiongain examines the prospects for antibacterial drugs from 2008-2013, including sales forecasts for leading pharmaceutical products. The antibacterial market is large in terms of disease area as well as \| more...	3/19/2008	$2,502.00
Google in Mobile 2008 By: Visiongain Google is the world’s most popular internet search engine. However with more people in the world having access to a mobile phone than a computer, Google is turning its attentions to the mobile market. Many \| more...	2/28/2008	$2,502.00
Generic League - Market Analysis and Forecasts, 2007-2012, 2017 & 2022 By: Visiongain The generic industry is a fast evolving market; with significant lucrative opportunities. The generic market is structurally set to experience high growth potential. That wave is partly driven by cost-containment in several national healthcare sectors \| more...	2/27/2008	$2,502.00
Google’s Android and Mobile Linux Report 2008 - A Google-led Initiative to Reshape the Mobile Market Environment By: Visiongain Google have launched the Android mobile operating system. The announcement was welcomed across large sections of the mobile industry, however the future prospects for this new Linux-based platform and for the shape of the mobile \| more...	2/23/2008	$2,502.00
Fixed-Mobile Convergence Market Analysis 2008 By: Visiongain The GSM Association is to test out a carrier ENUM service, which the trade body says will make it easier to send IMs, MMS, emails, videos and any other IP content between mobiles and fixed \| more...	2/21/2008	$2,502.00
The Antipsychotics Market Insight & Analysis 2008 By: Visiongain The total antipsychotics market revenue in 2006 was $18.1bn. Visiongain predicts that total revenues in the antipsychotics market will peak to $18.6bn by 2007. But what will it be in 2012? This report will tell \| more...	2/19/2008	$2,502.00
Mobile Social Networking and User Generated Content Market Insight 2008 By: Visiongain Vodafone have just announced a tie-up with Facebook for mobile phone activity. Facebook has launched a platform for operators designed to make its social networking application work better on portable devices. Vodafone is the first \| more...	2/12/2008	$2,502.00
Respiratory Market Insight 2008 By: Visiongain This brand new report examines the forthcoming prospects for respiratory drugs over the next 5 year. With in-depth sales forecasts for leading pharmaceutical products, the report has been produced to inform you of future developments \| more...	2/11/2008	$2,502.00
Erectile Dysfunction Market Assessment & Analysis 2007-2022 By: Visiongain The market for Erectile Dysfunction (ED) drugs is growing fast with a CAGR of 4.9% for the period 2006-2012. The ED market contains three leading drugs Viagra, Levitra and Cialis. Viagra, already a blockbuster drug, \| more...	2/1/2008	$2,210.00
Live-Licensing & In-life testing: R&D Processes and Regulation for New Drugs, 2008-2020 By: Visiongain Visiongain predict that the current phase I to IV clinical testing process will eventually be selectively or wholly replaced by a system known as “in-life” testing or “live” licensing. Those proposals involve cumulative testing of \| more...	1/17/2008	$2,502.00
UMTS 900 - Successfully Delivering 3G in Low-Frequency Bands By: Visiongain UMTS is now a firmly established technology. It is gaining mass market adoption, with DoCoMo admitting to having over 40 million 3G subs, and other markets also gaining a higher 3G penetration. As GSM is \| more...	1/8/2008	$2,502.00
Parkinson’s Disease Market analysis and forecasts, 2008-2012, 2017 &2022 By: Visiongain Parkinson's disease (PD) is the second most common neurological disorder, affecting approximately 4.1m people worldwide. As the prevalence rate of PD is set to rise significantly in the coming years, clinical interventions will play a \| more...	1/8/2008	$2,502.00
The World Dermatological Market Analysis & Forecasts 2007-2022 By: Visiongain Most skin disorders are not fatal but most people are affected globally. The revenue of dermatological market in 2006 was $16bn, which is a 5.1% when compared with 2003. The common skin disorders include acne, \| more...	11/26/2007	$2,210.00
Quad-Play and Service bundling strategy 2007-2012 By: Visiongain Are Virgin Media dropping quadplay? How effective is Tiscali’s quad-play strategy? Is neuf cegetel’s revenue increase thanks to Quad-play? These are just some of the questions this in-depth report will help you answer. Customers and \| more...	11/23/2007	$2,210.00
The Anti-Migraine Market 2007-2022 By: Visiongain Migraine is a serious neurological disorder characterised by recurrent headaches, varying in severity and frequency. Accounting for the loss of over 100 million working days in the US alone, the economic cost and social impact \| more...	11/13/2007	$2,210.00
Yahoo in Mobile, Analysis and Market Insight to 2012 By: Visiongain Yahoo, the number two Internet search engine, currently leads in mobile web destinations due to an aggressive play to capitalize on the still emerging mobile search and advertising space. Although the market has yet to \| more...	11/13/2007	$2,210.00
Alzheimer's Disease Market Analysis and Forecasts, 2007-2012, 2017 & By: Visiongain Alzheimers disease (AD) is the third leading cause of death in recent times and with an unprecedented patient potential, this disease area attracts awareness from a broad base of stake holders. With the grey population \| more...	10/15/2007	$2,210.00
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/22/2009 - 2